CDE-HM101 | 价格

CDE-HM101-100μg / 询价

CDE-HM101-500μg / 询价

CDE-HM101-500μgx2 / 询价

Human CD3E/CD3 epsilon Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human CD3E/CD3 epsilon Protein is expressed from HEK293 with His tag at the C-Terminus
It contains Asp23-Asp126 [Accession | P07766].

分子量大小(Molecular Weight)

The protein has a predicted MW of 12.6 kDa. Due to glycosylation, the protein migrates to 14-18 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1 EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Human CD3E on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Immobilized Human CD3E, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD3 Antibody, hFc Tag with the EC50 of 9.0 ng/ml determined by ELISA.

背景(Background)

CD3E, is a single-pass type I membrane protein.CD3 (cluster of differentiation 3) T cell co-receptor helps to activate both the cytotoxic T cell (CD8 naive T cells) and also T helper cells (CD4 naive T cells). It consists of a protein complex and is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains.

分子别名(Synonyms)

CD3e; CD3E; T3E; FLJ18683; TCRE; CD3-epsilon; IMD18

文献(References)

(1) Kroesen B J , Nieken J , Sleijfer D T , et al. Approaches to lung cancer treatment using the CD3E×GP-2-directed Bispecific Monoclonal Antibody BIS-1[J]. Cancer Immunology Immunotherapy, 1997, 45(3-4):203-206..